In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arrow Therapeutics Ltd.

Division of AstraZeneca PLC
www.arrowt.co.uk

Latest From Arrow Therapeutics Ltd.

INTERVIEW: Finding Stars And Staying Independent, Biotech Veteran David Chiswell's Five Year Plan

David Chiswell has worked tirelessly to build up the British biotech industry for over 30 years. Now, as CEO of Kymab, he is looking to the future of the industry and how to find the stars of the future.

United Kingdom Strategy

Deal Statistics Quarterly, Q1 2007

We present another installment of our quarterly review of dealmaking-for January-March 2007. Our data comes from Windhover's Strategic Transactions Database, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics and research industries.
BioPharmaceutical Medical Device

CEO Interview: AstraZeneca's David Brennan

David Brennan has sharpened AstraZeneca's therapeutic area focus and embraced external R&D. The next two years will determine whether the productivity drive is working--or if more radical change is needed.
BioPharmaceutical Europe

BMS Deals Diabetes Drugs, Solidifies Specialist Stance

The recent diabetes alliance between Bristol-Myers Squibb and AstraZeneca on two late-stage clinical compounds highlights some of the different ways pharmaceutical companies are embracing both specialty products and externalization strategies to address the industry's growing pipeline problem. BMS and AZ are pursuing different approaches but in diabetes, those strategies are complementary: AZ's unabashed externalization and muscular primary care marketing suits BMS's gradual weaning off the blockbuster model.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • AstraZeneca PLC
  • Senior Management
  • Ken Powell, CEO
    Ian Charles, CSO
    Piers Morgan, Dir., Fin.
    Margaret Walsh, Head., Bus. Dev.
  • Contact Info
  • Arrow Therapeutics Ltd.
    Phone: (44) 20 7015 1000
    Britannia House
    7 Trinity St.
    London, SE1
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register